Italia markets closed

Orgenesis Inc (45O.BE)

Berlin - Berlin Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,4740-0,0040 (-0,84%)
Alla chiusura: 08:08PM CEST
Schermo intero
Chiusura precedente0,4780
Aperto0,4700
Denaro0,4520 x N/D
Lettera0,5050 x N/D
Min-Max giorno0,4700 - 0,4740
Intervallo di 52 settimane0,2380 - 1,3400
Volume5.000
Media Volume114
CapitalizzazioneN/D
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili08 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States

    GERMANTOWN, Maryland, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the Point of Care (POCare) network and infrastructure of its advanced therapeutic services and facilities business through its subsidiary Octomera, by partnering with CGT Global, a biomedical company dedicated to advancing medical science and patient therapies. The

  • GlobeNewswire

    Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

    Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies

  • GlobeNewswire

    Orgenesis Provides Business Update for Second Quarter of 2023

    Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, “We are pleased to report